Bioorthogonal/Ultrasound Activated Oncolytic Pyroptosis Amplifies In Situ Tumor Vaccination for Boosting Antitumor Immunity
ACS Nano · 02.04.2024 · 18 (13) · 9413-9430
DOI: 10.1021/acsnano.3c11023 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 24.03.2024. Verfasst von Xiaoyu Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, CAS Key Laboratory of Biomedical Imaging Science and System, Institute of…. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Science and Technology Foundation of Shenzhen City, Basic and Applied Basic Research Foundation of Guangdong Province, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Personalized in situ tumor vaccination is a promising immunotherapeutic modality. Currently, seeking immunogenic cell death (ICD) to generate in situ tumor vaccines is still mired by insufficient immunogenicity and an entrenched immunosuppressive tumor microenvironment (TME). Herein, a series of tetrazine-functionalized ruthenium(II) sonosensitizers have been designed and screened for establishing a bioorthogonal-activated in situ tumor vaccine via oncolytic pyroptosis induction. Based on nanodelivery-augmented bioorthogonal metabolic glycoengineering, the original tumor is selectively remolded to introduce artificial target bicycle [6.1.0] nonyne (BCN) into cell membrane. Through specific bioorthogonal ligation with intratumoral BCN receptors, sonosensitizers can realize precise membrane-anchoring and synchronous click-activation in desired tumor sites. Upon ultrasound (US) irradiation, the activated sonosensitizers can intensively disrupt the cell membrane with dual type I/II reactive oxygen species (ROS) generation for a high-efficiency sonodynamic therapy (SDT). More importantly, the severe membrane damage can eminently evoke oncolytic pyroptosis to maximize tumor immunogenicity and reverse immunosuppressive TME, ultimately eliciting powerful and durable systemic antitumor immunity. The US-triggered pyroptosis is certified to effectively inhibit the growths of primary and distant tumors, and suppress tumor metastasis and recurrence in "cold" tumor models. This bioorthogonal-driven tumor-specific pyroptosis induction strategy has great potential for the development of robust in situ tumor vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, CAS Key Laboratory of Biomedical Imaging Science and System, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technol…
- College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
- Sino-Euro Center of Biomedicine and Health, Shenzhen 518024, China.
ORCID-Profile: Lintao Cai
Förderung
- Science and Technology Foundation of Shenzhen City
- Basic and Applied Basic Research Foundation of Guangdong Province
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Xu, X., Zheng, J., Liang, N., Zhang, X., Shabiti, S., Wang, Z., Yu, S., Pan, Z. Y., Li, W., & Cai, L. (2024). Bioorthogonal/Ultrasound Activated Oncolytic Pyroptosis Amplifies In Situ Tumor Vaccination for Boosting Antitumor Immunity. ACS Nano, 18(13), 9413-9430. https://doi.org/10.1021/acsnano.3c11023
Vancouver
Xu X, Zheng J, Liang N, Zhang X, Shabiti S, Wang Z, et al. Bioorthogonal/Ultrasound Activated Oncolytic Pyroptosis Amplifies In Situ Tumor Vaccination for Boosting Antitumor Immunity. ACS Nano. 2024;18(13):9413-9430. doi:10.1021/acsnano.3c11023
BibTeX
@article{Xu2024,
author = {Xu, Xiaoyu and Zheng, Jinling and Liang, Na and Zhang, Xu and Shabiti, Shayibai and Wang, Zixi and Yu, Shiwen and Pan, Zheng-Yin and Li, Wenjun and Cai, Lintao},
title = {Bioorthogonal/Ultrasound Activated Oncolytic Pyroptosis Amplifies In Situ Tumor Vaccination for Boosting Antitumor Immunity},
journal = {ACS Nano},
year = {2024},
volume = {18},
number = {13},
pages = {9413--9430},
doi = {10.1021/acsnano.3c11023}
}
EUVIMED